Presentation is loading. Please wait.

Presentation is loading. Please wait.

Evolution of Neoplasia The Uterine Cervix As a Model Raj C. Dash, MD Duke University Medical Center Durham, North Carolina.

Similar presentations


Presentation on theme: "Evolution of Neoplasia The Uterine Cervix As a Model Raj C. Dash, MD Duke University Medical Center Durham, North Carolina."— Presentation transcript:

1 Evolution of Neoplasia The Uterine Cervix As a Model Raj C. Dash, MD Duke University Medical Center Durham, North Carolina

2 What Medschool Class are You in ? 1.MS2014 2.MS 2015

3 Q: How do we screen for cervical cancer? 1.A) Blood test 2.B) X-ray or CT-imaging 3.C) Direct examination (colposcopy) 4.D) Slide test

4 Cancer of the Uterine Cervix History of Cervical Ca Screening Techniques –1925 - Hans Hanselman introduces colposcope. –1926 - Aureli Babes publishes on cytologic screening. Little publicity. –1928 - Papanicolaou presents findings on cytologic screening. –1941 - Papanicolaou publishes on cytologic screening. Widely read and accepted –1955 - Scheffey introduces colposcopy to the US. Dramatic decrease in mortality rate due to effectiveness of the Papanicolaou cytologic test in detecting precancerous lesions.

5 What site has highest incidence rate of cancer in women? 1.A) Cervix/Uterus 2.B) Pancreas 3.C) Thyroid 4.D) Ovary

6 What site has the highest death rate of cancer in women? 1.A) Cervix/Uterus 2.B) Pancreas 3.C) Thyroid 4.D) Ovary

7 Incidence Rate Death Rate

8 Cervical Cancer Epidemiology 20,000 new cases per year 7,600 deaths per year 3.5% of all female deaths per year 50 million women undergo Pap testing in the U.S. / year. 3.5 million (7%) are diagnosed with a cytological abnormality requiring additional follow-up or evaluation. JAMA. 2002;287:2120-2129.

9 Cervical Cancer Screening Epidemiologic Proof for Cervical Ca Screening - Why we do it... MacGregor (1976): –Screened women - invasive cancer rate = 30-50/100,000 –Unscreened women - invasive cancer rate = 310/100,000 Fidler (1968): –Screened women - invasive cancer rate = 5/100,000 –Unscreened women - invasive cancer rate = 29/100,000 Walton (1976): –Strong correlation between screening intensity and cervical cancer mortality (R=0.72) Adami (1994): –"Cytologic screening reduces mortality from cervical cancer by earlier diagnosis of invasive disease" Cancer 1994; 73:140-7.

10

11

12 Cervical Intraepithelial Neoplasia (CIN) Represents a continuum of morphologic changes with relatively indistinct boundaries –Dysplasia: abnormal cell growth Will not invariably progress to cancer –May spontaneously regress –Risk of progression to cancer increases with the severity of the “changes” observed Associated with viral infection?

13 Which virus is most closely associated with development of cervical cancer? 1.A) HIV 2.B) HPV 3.C) Hep B 4.D) Hep C 5.E) None of the above

14 HPV Human Papilloma Virus (HPV) –10 x risk increase of cervical neoplasia, found in 90% of CIN –Low Risk (6,11,42,43,44) –High Risk (16,18,31,33,35,39,45,51,52,56,58,59,68) –DiGene Hybrid Capture® HPV DNA Test (3/99)

15 Nomenclature Tumors are composed of proliferating neoplastic cells (clones) and supportive stroma of connective tissue and blood vessels. Tumors are named according to their neoplastic component.

16 Malignancy Nomenclature Carcinoma: malignant neoplasia arising from epithelial tissue. Sarcoma: malignant neoplasia arising from mesenchymal (connective) tissue. Lymphoma: malignant neoplasm arising from lymphoid tissue.

17 Nomenclature Carcinoma –Squamous cell carcinoma: derived from squamous epithelium. –Adenocarcinoma: derived from glandular epithelium.

18 Malignant Characteristics Rapid, Autonomous Growth –“Anaplasia” (uncontrolled growth bearing little similarity to cell of origin, implies progression beyond severe dysplasia, beyond well-differentiated malignancy; often associated with “poor differentiation”) Locally invasive Potential for metastatic spread –Lymphovascular invasion

19 Squamous Cell Neoplasia Traditional Pathology Nomenclature Current Pathology Nomenclature (CIN) Bethesda System Nomenclature (SIL) Squamous atypia ASCUS Condyloma Low Grade SIL (HPV effect) Mild DysplasiaCIN ILow Grade SIL (HPV effect) Moderate DysplasiaCIN IIHigh Grade SIL Severe DysplasiaCIN IIIHigh Grade SIL Carcinoma in-situCIN IIIHigh Grade SIL

20 Quick Quiz: Severe Dysplasia matches… 1.A) LSIL / CIN I 2.B) LSIL / CIN II 3.C) LSIL / CIN III 4.D) HSIL / CIN II 5.E) HSIL / CIN III

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45 Quick Recap: What cytologic criteria is LEAST important to identify neoplasia? 1.A) Nuclear size 2.B) Nuclear to cytoplasm size ratio 3.C) Cytoplasm (cell) size 4.D) Nuclear contours 5.E) Nuclear chromasia


Download ppt "Evolution of Neoplasia The Uterine Cervix As a Model Raj C. Dash, MD Duke University Medical Center Durham, North Carolina."

Similar presentations


Ads by Google